Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists

Journal of Medicinal Chemistry
Ramakrishna NirogiPradeep Jayarajan

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain. Because of this fascinating dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophores were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon analysis of focused structure-activity relationships, compound 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compound 4o in the novel-object-recognition-test cognition model.

References

Apr 1, 1997·Neuropharmacology·S LettyG Rondouin
Apr 1, 1997·Neuropharmacology·E Marchetti-GauthierB Soumireu-Mourat
Oct 5, 2001·The Journal of Biological Chemistry·S J RobertF Lezoualc'h
Jan 24, 2003·Journal of Medicinal Chemistry·Michel Langlois, Rodolphe Fischmeister
Jan 25, 2003·Experimental Gerontology·Frank Lezoualc'h, Sylvain J Robert
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·J BockaertA Dumuis
Jun 19, 2004·The Journal of Organic Chemistry·Wei Quan Tian, Yan Alexander Wang
Jun 25, 2005·Current Alzheimer Research·Marjorie MailletFrank Lezoualc'h
Mar 7, 2006·The Journal of Pharmacology and Experimental Therapeutics·Curtis R Kelly, Najam A Sharif
May 16, 2006·Digestive Diseases·Marcello Tonini, Fabio Pace
Feb 28, 2007·British Journal of Pharmacology·M Cachard-ChastelA M Gardier
Aug 19, 2007·Neuropharmacology·Eric G MohlerMichael E Ragozzino
Mar 7, 2008·Neuro-degenerative Diseases·Sylvain J Robert, Frank Lezoualc'h
Feb 24, 2011·Current Opinion in Pharmacology·Joël BockaertAline Dumuis
Mar 19, 2011·Journal of Medicinal Chemistry·Nicholas A Meanwell
Dec 22, 2011·Journal of Medicinal Chemistry·Jonas BoströmAlleyn T Plowright
Sep 15, 2012·Journal of Medicinal Chemistry·Michael A BrodneySarah Grimwood
Apr 23, 2013·The Journal of Pharmacy and Pharmacology·Ramakrishna NirogiMohammed Abdul Rasheed
Jun 13, 2013·Bioorganic & Medicinal Chemistry Letters·R Murray McKinnellRoss G Vickery
Jan 6, 2016·European Journal of Medicinal Chemistry·Ramakrishna NirogiRenny Abraham

❮ Previous
Next ❯

Citations

May 14, 2020·Expert Opinion on Therapeutic Patents·Caroline LanthierChristophe Rochais
Jan 31, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·José Ángel García-PedrazaAsunción Morán
Apr 4, 2021·International Journal of Molecular Sciences·Alejandro Castro-AlvarezRonald Nelson
Dec 22, 2021·Chemical Communications : Chem Comm·Thanh V Q NguyenAaron T Garrison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.